Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethanol versus gentamicin lock therapy for prevention of central venous catheter infection in pediatric intensive care
IRCT20221129056657N3Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Nov 2023
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of ethanol and gentamicin in Central venous catheter infection (CLABSI) (3 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Prevention of infection. Started Nov 2023; status: completed.
02
Drugs
ethanolgentamicin
03
Conditions
Central venous catheter infection (CLABSI)
Beyond the preview
Go deeper on IRCT20221129056657N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221129056657N3.